Recent Advances in Understanding Bisphosphonate Effects on Bone Mechanical Properties

[1]  P. Kostenuik.  On the evolution and contemporary roles of bone remodeling , 2021, Marcus and Feldman's Osteoporosis.

[2]  Nghia T. Vo,et al.  The effect of long-term bisphosphonate therapy on trabecular bone strength and microcrack density , 2017, Bone & joint research.

[3]  X. Nogués,et al.  Fracture during oral bisphosphonate therapy is associated with deteriorated bone material strength index. , 2017, Bone.

[4]  M. Allen.  Preclinical Models for Skeletal Research: How Commonly Used Species Mimic (or Don’t) Aspects of Human Bone , 2017, Toxicologic pathology.

[5]  D. Lorich,et al.  Atypical fracture with long-term bisphosphonate therapy is associated with altered cortical composition and reduced fracture resistance , 2017, Proceedings of the National Academy of Sciences.

[6]  Nghia T. Vo,et al.  Long-term effects of bisphosphonate therapy: perforations, microcracks and mechanical properties , 2017, Scientific Reports.

[7]  H. Malluche,et al.  Stiffness and strength of bone in osteoporotic patients treated with varying durations of oral bisphosphonates , 2016, Osteoporosis International.

[8]  K. Jepsen,et al.  Zoledronate treatment has different effects in mouse strains with contrasting baseline bone mechanical phenotypes , 2016, Osteoporosis International.

[9]  R. Ritchie,et al.  Intrinsic mechanical behavior of femoral cortical bone in young, osteoporotic and bisphosphonate-treated individuals in low- and high energy fracture conditions , 2016, Scientific Reports.

[10]  R. Ritchie,et al.  Alendronate treatment alters bone tissues at multiple structural levels in healthy canine cortical bone. , 2015, Bone.

[11]  Joseph M. Wallace,et al.  True Gold or Pyrite: A Review of Reference Point Indentation for Assessing Bone Mechanical Properties In Vivo , 2015, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[12]  J. Kornet,et al.  Effects of long-term alendronate treatment on bone mineralisation, resorption parameters and biomechanics of single human vertebral trabeculae. , 2014, European cells & materials.

[13]  D. Burr,et al.  The resistance of cortical bone tissue to failure under cyclic loading is reduced with alendronate. , 2014, Bone.

[14]  Jacques P. Brown,et al.  Bisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays. , 2014, Canadian family physician Medecin de famille canadien.

[15]  Thomas D Brown,et al.  Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Second Report of a Task Force of the American Society for Bone and Mineral Research , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[16]  R. Ritchie,et al.  Proposed Pathogenesis for Atypical Femoral Fractures: Lessons from Materials Research , 2022 .

[17]  A. Díez-Pérez,et al.  Microindentation for in vivo measurement of bone tissue material properties in atypical femoral fracture patients and controls , 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[18]  S. Silverman,et al.  Incidence of atypical nontraumatic diaphyseal fractures of the femur , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[19]  D. Burr,et al.  Bisphosphonate Binding Affinity Affects Drug Distribution in Both Intracortical and Trabecular Bone of Rabbits , 2012, Calcified Tissue International.

[20]  D. Burr,et al.  Bisphosphonate effects on bone turnover, microdamage, and mechanical properties: what we think we know and what we know that we don't know. , 2011, Bone.

[21]  A. Giusti,et al.  Atypical fractures of the femur and bisphosphonate therapy: A systematic review of case/case series studies. , 2010, Bone.

[22]  D. Burr,et al.  Changes in non-enzymatic glycation and its association with altered mechanical properties following 1-year treatment with risedronate or alendronate , 2009, Osteoporosis International.

[23]  D. Burr,et al.  Alendronate Reduces Bone Toughness of Ribs without Significantly Increasing Microdamage Accumulation in Dogs Following 3 Years of Daily Treatment , 2008, Calcified Tissue International.

[24]  M. Saito,et al.  Collagen maturity, glycation induced-pentosidine, and mineralization are increased following 3-year treatment with incadronate in dogs , 2008, Osteoporosis International.

[25]  P. Delmas,et al.  Bisphosphonates alter trabecular bone collagen cross-linking and isomerization in beagle dog vertebra , 2008, Osteoporosis International.

[26]  J. Zerwekh,et al.  Severely suppressed bone turnover: a potential complication of alendronate therapy. , 2005, The Journal of clinical endocrinology and metabolism.

[27]  D. Burr,et al.  Effects of high-dose etidronate treatment on microdamage accumulation and biomechanical properties in beagle bone before occurrence of spontaneous fractures. , 2001, Bone.

[28]  J. Lin,et al.  Bisphosphonates: a review of their pharmacokinetic properties. , 1996, Bone.